Drug Profile
NK 314
Alternative Names: NK314Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Nippon Kayaku
- Class Antineoplastics; Phenanthrenes
- Mechanism of Action DNA activated protein kinase inhibitors; DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours; T-cell lymphoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Japan (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in T-cell-lymphoma in Japan (Parenteral)
- 16 Apr 2008 Preclinical trials in T-cell lymphoma in Japan (unspecified route)